TW200640891A - Tartrate and malate salts of a pharmarceutical compound - Google Patents

Tartrate and malate salts of a pharmarceutical compound

Info

Publication number
TW200640891A
TW200640891A TW095104002A TW95104002A TW200640891A TW 200640891 A TW200640891 A TW 200640891A TW 095104002 A TW095104002 A TW 095104002A TW 95104002 A TW95104002 A TW 95104002A TW 200640891 A TW200640891 A TW 200640891A
Authority
TW
Taiwan
Prior art keywords
tartrate
pharmarceutical
compound
malate salts
malate
Prior art date
Application number
TW095104002A
Other languages
English (en)
Inventor
Ole Nielsen
Diego Heidi Lopez De
Benny Bang-Andersen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38006636&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200640891(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of TW200640891A publication Critical patent/TW200640891A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW095104002A 2005-02-16 2006-02-07 Tartrate and malate salts of a pharmarceutical compound TW200640891A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200500238 2005-02-16

Publications (1)

Publication Number Publication Date
TW200640891A true TW200640891A (en) 2006-12-01

Family

ID=38006636

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095104002A TW200640891A (en) 2005-02-16 2006-02-07 Tartrate and malate salts of a pharmarceutical compound

Country Status (7)

Country Link
KR (1) KR20070107043A (zh)
CN (1) CN101119982A (zh)
AR (1) AR053132A1 (zh)
EA (1) EA200701737A1 (zh)
IL (1) IL184531A0 (zh)
TW (1) TW200640891A (zh)
ZA (1) ZA200705461B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018927B1 (ru) * 2008-05-07 2013-11-29 Х. Лундбекк А/С Способ лечения когнитивного расстройства, ассоциированного с шизофренией
TW201102370A (en) * 2009-07-07 2011-01-16 Lundbeck & Co As H Manufacture of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl piperazine
EP2661427A1 (en) * 2011-01-07 2013-11-13 H. Lundbeck A/S Method for resolution of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1r,3s)-6-chloro-3-phenyl-indan, 1-yl)-3,3-dimethyl-piperazine

Also Published As

Publication number Publication date
IL184531A0 (en) 2007-10-31
EA200701737A1 (ru) 2007-12-28
KR20070107043A (ko) 2007-11-06
CN101119982A (zh) 2008-02-06
AR053132A1 (es) 2007-04-25
ZA200705461B (en) 2008-09-25

Similar Documents

Publication Publication Date Title
NO20074593L (no) Tartrat- og malatsalter av trans-1-(6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin
MY148108A (en) Medicaments for the treatment or prevention of fibrotic diseases
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
NO20061153L (no) Trans-1-(6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
TW200833663A (en) Therapeutic agents
HK1136292A1 (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
TW200500067A (en) Salts of codrugs and uses related thereto
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
TW200639156A (en) New compounds
TW200637544A (en) Medicaments for the treatment or prevention of fibrotic diseases
TW200612922A (en) Inhibitors of hsp90
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
BRPI0411891A (pt) pirazol[3,4-b]piridin-6-onas como inibidores de gsk-3
TW200640890A (en) Crystalline base of a pharmaceutical compound
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
TW200732304A (en) Piperidine derivatives
TW200640891A (en) Tartrate and malate salts of a pharmarceutical compound
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
HK1106246A1 (en) S-tenatoprazole monohydrated sodium salt and the use thereof in therapy s-
DE602005017629D1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
MY160005A (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone